The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.
Initial results from human clinical trials involving the use of bioengineered blood vessels could point the way to cost-effective alternative therapies for hemodialysis patients with end-stage renal disease.
Although they had more cardiovascular comorbidities, patients with atrial fibrillation and diabetes experienced rates of ischemic stroke comparable to those in AF patients without diabetes.
Study results show hyponatremia is closely associated with all-cause mortality in patients with chronic kidney disease (CKD), but few previous studies have examined this relationship.
Patients who have chronic kidney disease (CKD) and end-stage renal disease (ESRD) require 20% less warfarin and more monitoring for bleeding than patients who have normal kidney function.
A recent study presented at Kidney Week 2013 suggests that a plain X-ray is a reliable and inexpensive tool for assessing the risks of cardiovascular events and death in patients who have chronic kidney disease (CKD) and are not on dialysis.
Randomized controlled trials remain the gold standard, but a researcher at Kidney Week 2012 says that new approaches and study designs are needed that reflect real-world drug use and account for confounding variables.
Results from the TEMPO trial presented at Kidney Week 2012 show that treatment with tolvaptan slowed the increase in total kidney volume and the decline in kidney function in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Increasing numbers of people are on kidney transplant waiting lists. However, the number of potential living donors may shrink as more Americans qualify as pre-diabetic, making them less than ideal donor candidates.
The powerful immunosuppressive drugs used to prevent allograft rejection are associated with severe side effects. A "mixed chimerism" strategy in which patients undergo simultaneous bone marrow and kidney transplant from the same donor may improve transplant survival and reduce the need for these drugs.
Use of peritoneal dialysis in patients with end-stage renal disease is declining due to lack of physician training and awareness, financial disincentives, and other factors. However, with proper patient and provider education, it is possible to grow a successful peritoneal dialysis program.
Study results reported at Kidney Week 2012 reveal that patients with early-stage CKD fare better in the public health system, which also appears to produce fewer racial and ethnic health disparities in care delivered to this population.